Prof. Pradeep Nathan is Vice President and Head, CNS Clinical Development and Experimental Medicine at Heptares Therapeutics Ltd. He is also Professor of Neuroscience at Monash University and an affiliated lecturer at the University of Cambridge.
Pradeep trained as a pharmacologist and cognitive neuroscientist. His research focusses on the understanding of the neural substrates of cognition and psychiatric and neurological endophenotypes using behavioural and imaging methods and applying these approaches to drug discovery through development of molecular and functional biomarkers which might aid in the development of more refined and targeted treatment approaches for cognitive and emotional dysfunction in psychiatric and neurological disorders. Pradeep has over 10 years of industry experience in the translational and clinical development of CNS compounds while working at GSK, UCB Pharma and Heptares Therapeutics. He has also published over 200 peer reviewed papers which have been cited over 10,000 times. His research has been recognised by a number of awards including the Australian tall poppy science award, the British Association of Psychopharmacology, clinical research award and the prestigious fellowship of the American College of Neuropsychopharmacology.